Formulation, Development, and In Vitro Evaluation of a CD22 Targeted Liposomal System Containing a Non-Cardiotoxic Anthracycline for B Cell Malignancies

Formulation, Development, and In Vitro Evaluation of a CD22 Targeted Liposomal System Containing a Non-Cardiotoxic Anthracycline for B Cell Malignancies

Doxorubicin cardiotoxicity has led to the development of superior chemotherapeutic agents such as AD 198. However, depletion of healthy neutrophils and thrombocytes from AD 198 therapy must be limited. This can be done by the development of a targeted drug delivery system that delivers AD 198 to the...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Nivesh K. Mittal, Bivash Mandal, Pavan Balabathula, Saini Setua, Dileep R. Janagam, Leonard Lothstein, Laura A. Thoma, George C. Wood
Formatua: Artikulua
Hizkuntza:English
Argitaratua: MDPI AG 2018-04-01
Saila:Pharmaceutics
Gaiak:
AD 198
B-cell malignancy
liposome
nanoparticle
CD22 targeting
Sarrera elektronikoa:http://www.mdpi.com/1999-4923/10/2/50

Internet

http://www.mdpi.com/1999-4923/10/2/50

Antzeko izenburuak